Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	548.14	471.68	752	731.28	791.99	1,346
Short-Term Investments	-	-	-	-	-	190
Trading Asset Securities	49.63	126.44	0.54	-	201.01	-
Cash & Short-Term Investments	597.77	598.12	752.54	731.28	993	1,536
Cash Growth	7.79%	-20.52%	2.91%	-26.36%	-35.35%	194.64%
Accounts Receivable	158.52	98.47	286.41	450.62	173.38	52.61
Other Receivables	0.65	1.83	2.61	49.7	40.75	6.81
Receivables	159.16	100.3	289.02	500.32	214.13	59.42
Inventory	302.96	290.09	327.5	372.17	293.32	188.59
Prepaid Expenses	-	-	0.2	-	-	-
Other Current Assets	241.83	235.82	156.62	129.06	153.49	63.91
Total Current Assets	1,302	1,224	1,526	1,733	1,654	1,848
Property, Plant & Equipment	2,958	3,009	2,574	2,056	1,331	775.72
Long-Term Investments	1,274	1,437	1,382	919.27	345.79	274.55
Goodwill	413.58	413.58	413.58	413.58	413.58	413.58
Other Intangible Assets	2,686	2,776	1,944	1,219	1,183	603.37
Long-Term Deferred Tax Assets	56.67	56.73	39.13	85.96	55.06	55.22
Long-Term Deferred Charges	395.14	383.53	1,219	1,444	1,252	1,171
Other Long-Term Assets	40.18	41.99	50.3	39.3	37.6	87.79
Total Assets	9,126	9,342	9,147	7,910	6,271	5,230
Accounts Payable	601.25	746.11	800.12	35.85	431.19	113.62
Accrued Expenses	85.44	285.53	357.82	419.11	357.02	187.53
Short-Term Debt	200.16	100.08	300.27	380.39	-	-
Current Portion of Long-Term Debt	1,003	639.85	301.25	-	-	-
Current Portion of Leases	-	33.03	4.6	4.16	4.88	-
Current Income Taxes Payable	55.83	4.26	0.07	0.04	10.68	27.54
Current Unearned Revenue	4.5	2.63	4.92	4.46	0.69	1.27
Other Current Liabilities	142.22	36.47	34.11	1,261	84.4	108.14
Total Current Liabilities	2,092	1,848	1,803	2,105	888.86	438.1
Long-Term Debt	1,122	1,552	1,816	656.03	-	2.6
Long-Term Leases	63.09	71.63	8.18	7.3	6.34	-
Long-Term Unearned Revenue	195.6	150.99	144.7	112.76	112	58.01
Long-Term Deferred Tax Liabilities	21.59	53.49	23.39	71.57	68.39	64.64
Other Long-Term Liabilities	-	-	-	-	510.06	521.99
Total Liabilities	3,494	3,676	3,795	2,952	1,586	1,085
Common Stock	418.49	418.49	418.49	417.47	415.39	413.16
Additional Paid-In Capital	2,084	1,945	1,945	1,860	1,932	1,793
Retained Earnings	2,934	2,834	2,503	2,181	2,139	1,883
Comprehensive Income & Other	107.33	375.78	384.48	390.99	74.64	52.28
Total Common Equity	5,544	5,574	5,251	4,849	4,561	4,141
Minority Interest	87.62	92.3	100.4	108.64	124.9	3.41
Shareholders' Equity	5,631	5,666	5,351	4,958	4,686	4,144
Total Liabilities & Equity	9,126	9,342	9,147	7,910	6,271	5,230
Total Debt	2,388	2,396	2,430	1,048	11.22	2.6
Net Cash (Debt)	-1,790	-1,798	-1,678	-316.59	981.77	1,533
Net Cash Growth	-	-	-	-	-35.97%	-
Net Cash Per Share	-4.29	-4.29	-4.00	-0.76	2.36	3.77
Filing Date Shares Outstanding	418.49	418.49	418.49	417.47	415.39	413.16
Total Common Shares Outstanding	418.49	418.49	418.49	417.47	415.39	413.16
Working Capital	-790.69	-623.63	-277.28	-371.95	765.08	1,410
Book Value Per Share	13.25	13.32	12.55	11.62	10.98	10.02
Tangible Book Value	2,444	2,384	2,894	3,216	2,964	3,124
Tangible Book Value Per Share	5.84	5.70	6.92	7.70	7.14	7.56
Buildings	-	2,952	586.14	585.59	627.19	588.32
Machinery	-	449.64	424.26	402.25	376.01	339.24
Construction In Progress	-	191.87	2,037	1,448	639.67	63.12

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.